Skip to main content
SpringerLink
Log in

Erlotinib appears cost effective for NSCLC in Taiwan

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Yang S-C, et al. Comparative effectiveness and cost-effectiveness of three first-line EGFR-tyrosine kinase inhibitors: Analysis of real-world data in a tertiary hospital in Taiwan. PLOS One : 8 Apr 2020. Available from: URL: https://doi.org/10.1371/journal.pone.0231413

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Erlotinib appears cost effective for NSCLC in Taiwan. PharmacoEcon Outcomes News 851, 20 (2020). https://doi.org/10.1007/s40274-020-6743-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-020-6743-3

Search

Navigation